14 February 2019 in Oxidative Medicine and Cellular Longevity
Several researches revealed that propofol, a hypnotic intravenous anesthesia agent, could inhibit the cancer cell proliferation and tumor formation, which might affect cancer recurrence or metastasis and impact patients’ prognosis. Cancer stem cells (CSCs) comprised a tiny fraction of tumor bulk and played a vital role in cancer recurrence and eventual mortality. This study investigates the effect of propofol on breast cancer stem cells (BCSCs) in vitro and the underlying molecular mechanisms. Tumor formation of CSCs was measured by mammosphere culture. Cultured BCSCs were exposed to different concentrations and durations of propofol. Cell proliferation and self-renewal capacity were determined by MTT assays. Expressions of PD-L1 and Nanog were measured using western blotting and real-time PCR. We knocked down the PD-L1 expression in MDA-MB-231 cells by lentivirus-mediated RNAi technique, and the mammosphere-forming ability of shControl and shPD-L1 under propofol treatment was examined. Mammosphere culture could enrich BCSCs. Compared with control, cells exposed to propofol for 24 h induced a larger number of mammosphere cells (). Levels of PD-L1 and Nanog were downregulated by propofol. Compared with shControl stem cells, there was no significant difference in the inhibitory effect of propofol on the mammosphere-forming ability of shPD-L1 stem cells which indicated that the inhibition of propofol could disappear in PD-L1 knockdown breast stem cells. Propofol could reduce the mammosphere-forming ability of BCSCs in vitro. Mechanism experiments indicated that the inhibition of propofol in mammosphere formation of BCSCs might be mediated through PD-L1, which was important to maintain Nanog.
1 January 2018 in Oxidative Medicine and Cellular Longevity
We aimed to evaluate the cardioprotective effect and mechanism of propofol in anthracycline‐induced cardiomyocyte apoptosis. We selected the rat myocardial cell line, H9c2, and primary cardiomyocytes for in vitro study. The cardiomyocytes were treated with vehicle, Adriamycin® (ADM), propofol, or a combination of ADM and propofol. The proportion of apoptotic cells and the expression of miR‐181a were detected by flow cytometry and real‐time PCR, respectively. Luciferase assays were performed to explore the direct target gene of miR‐181a. In vivo assay, rats were randomly divided into different treatment groups. The apoptosis index was determined by TUNEL staining, and the expression of miR‐181a and STAT3 in heart tissue was detected. The antiproliferative effect of ADM alone was significantly greater than that of ADM plus propofol. A significantly greater decrease in the proportion of apoptotic cells and in miR‐181a expression was observed in the combination treatment group compared with that in the ADM groups in vitro and in vivo. The loss‐of‐function of miR‐181a in H9c2 of ADM treatment resulted in increased Bcl‐2 and decreased Bax. MiR‐181a suppressed Bcl‐2 expression through direct targeting of the Bcl‐2 transcript. Propofol reduced anthracycline‐induced apoptosis in cardiomyocytes via targeting miR‐181a/Bcl‐2, and a negative correlation between miR‐181a and Bcl‐2 was observed.
1 April 2025 in Cardiovascular Diagnosis and Therapy
Original Article Investigating the causal relationship between genetically determined metabolites and ischemic stroke functional outcomes: a Mendelian randomization study Xiaobei Zhang, Gehong Liang, Ying Zheng, Xiaokun Wang, Weihao Luo, Guiyue Wang, Yiqing Yin